Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, VitaNova Life Sciences's share price is $1.38.
VitaNova Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was $0.36. Hence, VitaNova Life Sciences's PS Ratio for today is 3.81.
The historical rank and industry rank for VitaNova Life Sciences's PS Ratio or its related term are showing as below:
VNOV'
s PS Ratio Range Over the Past 10 Years
Min: 1.33 Med: 23.08 Max: 750
Current: 3.81
During the past 10 years, VitaNova Life Sciences's highest PS Ratio was 750.00. The lowest was 1.33. And the median was 23.08.
VNOV's PS Ratio is not ranked
in the Medical Distribution industry.
Industry Median: 0.4
vs VNOV: 3.81
During the past 10 years, VitaNova Life Sciences's highest 3-Year average Revenue per Share Growth Rate was 167.30% per year. The lowest was 73.60% per year. And the median was 120.45% per year.
VitaNova Life Sciences (OTCPK:VNOV) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, VitaNova Life Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VitaNova Life Sciences PS Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, VitaNova Life Sciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where VitaNova Life Sciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
VitaNova Life Sciences's Share Price of today is $1.38. VitaNova Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.36.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
VitaNova Life Sciences (VNOV) has a PS Ratio of 3.81 as of Aug. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on VitaNova Life Sciences and its competitors. This is 83% below median its historical median of 23.08. Over the past decade, VitaNova Life Sciences' PS Ratio has ranged from 1.33 to 750.00.
Is VitaNova Life Sciences' PS Ratio too high?
VitaNova Life Sciences' current PS Ratio of 3.81 is 83% below median its 10-year median of 23.08. Over the past 10 years, this metric has ranged from a low of 1.33 to a high of 750.00. The Medical Distribution industry median PS Ratio is 0.40. VitaNova Life Sciences' value of 3.81 is 852.5% above this industry median. Overall, VitaNova Life Sciences has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does VitaNova Life Sciences' PS Ratio compare to HKPD and COSM?
VitaNova Life Sciences' PS Ratio of 3.81 can be compared against companies in the Medical Distribution industry. The industry median PS Ratio is 0.40. VitaNova Life Sciences' value of 3.81 is 852.5% above this benchmark. Historically, VitaNova Life Sciences' own PS Ratio has ranged from 1.33 to 750.00 over the past decade. While the company's 10-year median is 23.08 vs. the industry median of 0.40, VitaNova Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Distribution company?
The median PS Ratio among Medical Distribution companies is 0.40, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VitaNova Life Sciences's current PS Ratio of 3.81 is 852.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on VitaNova Life Sciences and its competitors. For the Medical Distribution industry, the median PS Ratio is 0.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VitaNova Life Sciences's current PS Ratio is 3.81, which is 83% below median its own 10-year median of 23.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VitaNova Life Sciences stock overvalued right now?
VitaNova Life Sciences (VNOV) has a current PS Ratio of 3.81. The stock's GF Value™ is $5.95, compared to a current price of $1.38 — trading 76.8% below its estimated fair value. The current PS Ratio is 3.81, which is 83% below median its 10-year median of 23.08 and 852.5% above the Medical Distribution industry median of 0.40. VitaNova Life Sciences' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For VitaNova Life Sciences (VNOV), the current PS Ratio is 3.81 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VitaNova Life Sciences (VNOV) Overvalued in 2026?
Based on GuruFocus' analysis, VitaNova Life Sciences stock appears to be undervalued.
The current stock price of $1.38 is trading 76.8% below its estimated GF Value™ of $5.95.
Key valuation signals for VNOV:
PS Ratio: 3.81 (83% below median its 10-year median of 23.08)
GF Value™: $5.95 vs. price of $1.38 (76.8% below fair value)
Industry Position: 852.5% above the Medical Distribution median
No single metric tells the full story. See the VNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VitaNova Life Sciences Corp, formerly Yijia Group Corp provides business consulting services to domestic and international customers. The Company provides consulting services to its clients with regards to funding and other financial matters.The company's operating segments are The consulting services Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers. The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. and the majority of its revenue generates from Sales of healthcare products.
51GF Score
Get the complete analysis for VNOV
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VNOV has been successfully added to your 
